Harvey Investment Co. LLC Has $33.76 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Harvey Investment Co. LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.0% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 203,595 shares of the company's stock after selling 2,034 shares during the quarter. Johnson & Johnson makes up 3.7% of Harvey Investment Co. LLC's holdings, making the stock its 6th largest holding. Harvey Investment Co. LLC's holdings in Johnson & Johnson were worth $33,764,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Lantz Financial LLC increased its holdings in Johnson & Johnson by 3.3% in the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after acquiring an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $453,000. Horan Securities Inc. increased its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares during the last quarter. State of Wyoming boosted its holdings in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the period. Finally, Range Financial Group LLC boosted its stake in Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.0%

Shares of NYSE:JNJ traded down $0.03 during trading hours on Thursday, hitting $152.25. The company's stock had a trading volume of 7,147,523 shares, compared to its average volume of 8,011,647. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The firm's fifty day moving average price is $153.85 and its 200 day moving average price is $153.69. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market capitalization of $366.33 billion, a price-to-earnings ratio of 16.94, a P/E/G ratio of 2.31 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Raymond James Financial lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.